REBECCA DARLAGE: Open Payments
NPI 1285353227 · SEYMOUR, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,771 in 95 payments from 20 companies in 2025. Trend: 2023 $635 · 2024 $1,734 · 2025 $1,771
Food & beverage: $1,771
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $312 |
| Novo Nordisk Inc | 14 | $202 |
| AstraZeneca Pharmaceuticals LP | 8 | $187 |
| PFIZER INC. | 7 | $139 |
| Merck Sharp & Dohme LLC | 7 | $117 |
| GlaxoSmithKline, LLC. | 6 | $109 |
| Madrigal Pharmaceuticals | 3 | $106 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Amgen Inc. | 5 | $74 |
Products named: VRAYLAR, REZDIFFRA, Rybelsus, REXULTI, TRELEGY ELLIPTA, Auvelity, JARDIANCE, PIFELTRO.
Industry payments across IN — which companies pay providers there.
